Longeveron to Explore All Options After Phase 2b Failure in Rare Pediatric Heart Condition
ELPIS II missed its primary endpoint in HLHS. Longeveron plans an FDA talk, cost cuts, and a strategic review as cash runs into Q4 2026.
/ 1642 items
#XY↓
Twist and Ginkgo Join Lilly’s TuneLab to Speed Antibody Discovery With AI and Lab Data
Twist Bioscience and Ginkgo Datapoints join Eli Lilly’s TuneLab to pair lab testing with AI for faster antibody drug discovery.
Barclays Upgrades Alvotech to Overweight, Doubles Target to $8 Ahead of December FDA Decisions
Barclays now sees two-times upside vs. downside for ALVO into December FDA reviews of Simponi, Eylea and Prolia biosimilars.
Xenetic and Santersus Combine to Build a Nasdaq Company Targeting Neutrophil Extracellular Traps
NucleoCapture and DNase will target NETs in sepsis, lupus, transplant and lymphoma.
Needham Upgrades Rocket Pharmaceuticals After FDA Clears Path for Danon Gene Therapy Trial
FDA let Rocket keep its 12-patient Danon study and count the first 3 patients. Needham upgraded RCKT and removed a key regulatory overhang.
Tempest Adds Second In-Vivo CAR-T Approach with Senlang Deal
Tempest gets an exclusive option to license Senlang’s CD7-targeted lentiviral in-vivo CAR-T, now in Phase 1 for relapsed multiple myeloma.